The prognostic significance and therapeutic potential of the TLR 7/8 pathway in CNS lymphomas

A Phase I/II trial exploring tafasitamab plus lenalidomide in relapsed CNS lymphoma

Tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma

CXCL10-CXCR3 signaling as a pro-survival pathway and prognostic biomarker in CNS lymphoma

BTK degradation as a novel therapeutic strategy for relapsed CNS lymphoma

Tafasitamab at the blood-brain barrier: exploring this agent for the treatment of CNS lymphoma

Identification of genomic biomarkers of disease progression & survival in primary CNS lymphoma